Table 3.
Adverse events in 64 patients with sarcoma treated with apatinib
| Adverse eventsa | Grade 1 | Grade 2 | Grade 3 | Total |
|---|---|---|---|---|
| Hypertension | 11 | 8 | 5 | 24(37.50%) |
| Hand-foot syndrome | 9 | 10 | 3 | 22(34.38%) |
| Proteinuria | 11 | 6 | 2 | 19(29.69%) |
| Anorexia | 10 | 4 | 14(21.88%) | |
| Fatigue | 7 | 2 | 1 | 8(12.50%) |
| Pain | 4 | 2 | 1 | 7(10.94%) |
| Diarrhea | 6 | 1 | 7(10.94%) | |
| Mucositis | 3 | 2 | 5(7.81%) | |
| Skin pigmentation | 5 | 5(7.81%) | ||
| Rash | 5 | 5(7.81%) | ||
| Transaminase increased | 3 | 1 | 4(6.25%) | |
| Anemia | 4 | 4(6.25%) | ||
| Hiccough | 4 | 4(6.25%) | ||
| Bilirubin increased | 2 | 1 | 3(4.69%) | |
| Dyspnea | 2 | 1 | 3(4.69%) | |
| Periodontal disease | 3 | 3(4.69%) | ||
| Aerothorax | 1 | 1 | 2(3.13%) | |
| Hematuria | 2 | 2(3.13%) | ||
| Dizziness | 2 | 2(3.13%) | ||
| Palpitation | 2 | 2(3.13%) | ||
| Hypogeusia | 1 | 1(1.56%) | ||
| Fever | 1 | 1(1.56%) |
aAccording to CTCAE 4.0